Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1548)	12/23/1998 1:06:00 AM
From: Toby Zidle	Read Replies (1) \| Respond to of 2173

Thanks for the compliment, David. The reward/risk - statistical approach to investing seems intuitively obvious. My model was quite simple, with the major risk being bankruptcy. Anyone can fine-tune this method with different risk (odds) estimates and multiple price-slices. Depending on different assumptions, an argument might be made against buying AMLN. My opinion, though, is that most models make AMLN an attractive buy and if price drops, AMLN only becomes more attractive. As I said also, AMLN is not an 'investment'. It's a 'speculation', nevertheless stacking up well against a call option purchase of many other stocks. I'm staying long on AMLN.